TY - JOUR
T1 - Self-reported incident hypertension and long-term kidney function in living kidney donors compared with healthy nondonors
AU - Holscher, Courtenay M.
AU - Haugen, Christine E.
AU - Jackson, Kyle R.
AU - Garonzik Wang, Jacqueline M.
AU - Waldram, Madeleine M.
AU - Bae, Sunjae
AU - Locke, Jayme E.
AU - Reed, Rhiannon D.
AU - Lentine, Krista L.
AU - Gupta, Gaurav
AU - Weir, Matthew R.
AU - Friedewald, John J.
AU - Verbesey, Jennifer
AU - Cooper, Matthew
AU - Segev, Dorry L.
AU - Massie, Allan B.
N1 - Funding Information:
This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (F32DK109662, F32DK113719, K01DK101677, K23DK103918, K24DK101828, and R01DK096008); and the National Institute on Aging (F32AG053025) and an American College of Surgeons Resident Research Scholarship.
Funding Information:
This manuscript was prepared using Atherosclerosis Risk in Communities (ARIC) and Coronary Artery Risk Development in Young Adults (CARDIA) research materials obtained from the National Heart, Lung, and Blood Institute (NHLBI) Biologic Specimen and Data Repository Information Coordinating Center and does not necessarily reflect the opinions or views of the ARIC, the CARDIA, or the NHLBI. The analyses described here are the responsibility of the authors alone and do not necessarily reflect the views or policies of the Department of Health and Human Services nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government. Funding This work was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (F32DK109662, F32DK113719, K01DK101677, K23DK103918, K24DK101828, and R01DK096008); and the National Institute on Aging (F32AG053025) and an American College of Surgeons Resident Research Scholarship.
Funding Information:
Dr. Friedewald reports grants, personal fees, and other fees from Transplant Genomics, Inc.; grants from Shire; grants and personal fees from Abbvie; personal fees from Viela Bio; personal fees from Novartis; personal fees from Sanofi; grants from Vaiteris; and personal fees from American Society of Nephrology, outside the submitted work. Dr. Gupta has received honoraria from CareDx, Mallinckrodt Pharmaceuticals, and One Lambda/Thermo Fisher for sponsored presentations and research support from Gilead Pharmaceuticals, outside the submitted work. Dr. Locke reports honorarium, payment for development of educational presentations, and payment for lectures, including service on a speakers bureau, from Sanofi outside the submitted work. Dr. Weir reports personal fees from Relypsa and personal fees from ZS Pharma during the conduct of the study. Dr. Weir reports personal fees from AbbVie, Akebia, Amgen, AstraZeneca, Boston Scientific, Janssen, MSD, Novartis, and Sandoz, outside the submitted work. The remaining authors have nothing to disclose.
Publisher Copyright:
© 2019 by the American Society of Nephrology.
PY - 2019/10/7
Y1 - 2019/10/7
N2 - Background and objectives The risk of hypertension attributable to living kidney donation remains unknown as does the effect of developing postdonation hypertension on subsequent eGFR. We sought to understand the association between living kidney donation, hypertension, and long-term eGFR by comparing donors with a cohort of healthy nondonors. Design, setting, participants, & measurements We compared 1295 living kidney donors with median 6 years of follow-up with a weighted cohort of 8233 healthy nondonors. We quantified the risk of self-reported hypertension using a parametric survival model. We examined the association of hypertensionwith yearly change in eGFR using multilevel linear regression and clustering by participant, with an interaction term for race. Results Kidney donation was independently associated with a 19% higher risk of hypertension (adjusted hazard ratio, 1.19; 95% confidence interval, 1.01 to 1.41; P=0.04); this association did not vary by race (interaction P=0.60). For white and black nondonors, there was a mean decline in eGFR (20.4 and 20.3 ml/min per year, respectively) that steepened after incident hypertension (20.8 and 20.9 ml/min per year, respectively; both P,0.001). For white and black kidney donors, there was a mean increase in eGFR after donation (+0.4 and +0.6 ml/min per year, respectively) that plateaued after incident hypertension (0 and 20.2 ml/min per year, respectively; P=0.07 and P=0.01, respectively, after hypertension). Conclusions Kidney donors are at higher risk of hypertension than similar healthy nondonors, regardless of race. Donors who developed hypertension had a plateau in the usual postdonation increase of eGFR.
AB - Background and objectives The risk of hypertension attributable to living kidney donation remains unknown as does the effect of developing postdonation hypertension on subsequent eGFR. We sought to understand the association between living kidney donation, hypertension, and long-term eGFR by comparing donors with a cohort of healthy nondonors. Design, setting, participants, & measurements We compared 1295 living kidney donors with median 6 years of follow-up with a weighted cohort of 8233 healthy nondonors. We quantified the risk of self-reported hypertension using a parametric survival model. We examined the association of hypertensionwith yearly change in eGFR using multilevel linear regression and clustering by participant, with an interaction term for race. Results Kidney donation was independently associated with a 19% higher risk of hypertension (adjusted hazard ratio, 1.19; 95% confidence interval, 1.01 to 1.41; P=0.04); this association did not vary by race (interaction P=0.60). For white and black nondonors, there was a mean decline in eGFR (20.4 and 20.3 ml/min per year, respectively) that steepened after incident hypertension (20.8 and 20.9 ml/min per year, respectively; both P,0.001). For white and black kidney donors, there was a mean increase in eGFR after donation (+0.4 and +0.6 ml/min per year, respectively) that plateaued after incident hypertension (0 and 20.2 ml/min per year, respectively; P=0.07 and P=0.01, respectively, after hypertension). Conclusions Kidney donors are at higher risk of hypertension than similar healthy nondonors, regardless of race. Donors who developed hypertension had a plateau in the usual postdonation increase of eGFR.
UR - http://www.scopus.com/inward/record.url?scp=85072994393&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072994393&partnerID=8YFLogxK
U2 - 10.2215/CJN.04020419
DO - 10.2215/CJN.04020419
M3 - Article
C2 - 31537534
AN - SCOPUS:85072994393
SN - 1555-9041
VL - 14
SP - 1493
EP - 1499
JO - Clinical Journal of the American Society of Nephrology
JF - Clinical Journal of the American Society of Nephrology
IS - 10
ER -